Механизмы устойчивости опухолей к цисплатину
Biol Chem 1994; 269: 29085-93.
35. Goto S, Yoshido K, MoriKawa T, Urata Y, Suzuki K,. Kondo T.
Augmentation of transport for cisplatin-glutathione adduct in
cisplatin-resistant cancer cells. Cancer Res 1995; 55: 4297-301.
36. Veneroni S, Zaffaroni N, Daidone MG, Benini E, Villa R,
Silvestrini R. Expression of P-glycoprotein and in vitro or in vivo
resistance to doxorubicin and cisplatin in breast and ovarian
cancers. Eur J Cancer 1994; 30A: 1002-7.
37. Jedlitschky G, Leier J, Buchholz U, Barnouin K, Kurz G, Keppler
D. Transport of glutathione, glucuronate, and sulfate conjugates by
the MRP gene-encoded conjugate export pump. Cancer Res 1996; 56: 988-
94.
38. Okuyama T, Maehara Y, Endo K, Baba H, Adachi Y, Kuwano M,
Sugimachi K. Expression of glutathione S-transferase-pi and
sensitivity of human gastric cancer cells to cisplatin. Cancer 1994;
74: 1230-6.
39. Awasthi S, Sharma R, Singhal SS, Herzog NK, Chaubey M, Awasthi
YC. Modulation of cisplatin cytotoxicity by sulphasalazine. Br J
Cancer 1994; 70: 190-4.
40. Bongers V, Snow GB, Braakhuis BJM. The role of glutathione S-
transferases in head and neck squamous cell carcinogenesis. Eur J
Cancer 1995; 31B: 349-54.
41 Minagawa Y, Kigawa J, Ishihara H, Itamochi H, Terakawa N.
Synergistic enhancement of cisplatin cytotoxicity by SN-38, an active
metabolite of CPT-11, for cisplatin-resistant HeLa cells. Jpn J
Cancer Res 1994; 85: 966-71.
42. Boscia RE, Korbut T, Holden SA, Ara G, Teicher BA. Interaction of
topoisomerase I inhibitors with radiation in cis-
Diamminedichloroplatinum (II)-sensitive and -resistant cells in vitro
and in the FSAIIC fibrosarcoma in vivo. Int J Cancer 1993; 53: 118-
23.
43. Kikuchi Y, Hirata J, Yamamoto K, Ishi K, Kita T, Kudoh K, Tode
T, Nagata I, Taniguchi K, Kuwano M. Altered expression of ?-
glutamylcysteine synthetase, metallothionein and topoisomerase I or
II during acquisition of drug resistance to cisplatin in human
ovarian cancer cells. Jpn J Cancer Res 1997; 88: 213-7.
44. Hirata J, Kikuchi Y, Kita T, Imaizumi EE, Tode T, Ishii K, Kudoh
K, Nagata I. Modulation of sensitivity of human ovarian cancer cells
to cis-diamminedichloroplatinum (II) by 12-O-tetradecanoylphorbol-13-
acetate and D,L-Buthionine-S,R-Sulphoximine. Int J Cancer 1993; 55:
521-7.
45.Sugimoto C, Matsukawa S, Fujieda S, Noda I, Tanaka N, Tsuzuki H,
Saito H. Involvement of intracellular glutathione in induction of
apoptosis by cisplatin in a human pharyngeal carcinoma cell line.
Anticancer Res 1996; 16: 675-80.
46. Pendyala L, Perez R, Weinstein A, Zdanowicz J, Creaven PJ. Effect
of glutathione depletion on the cytotoxicity of cisplatin and
iproplatin in a human melanoma cell line. Cancer Chemother Pharmacol
1997, 40 (1): 38-44.
47. Kurokawa H, Nishio K, Ishida T, Arioka H, Fukuoka K, Nomoto T,
Fukumoto H, Yokote H, Saijo N. Effect of glutathione depletion on
cisplatin resistance in cancer cells transfected with the ?
-glutamylcysteine synthetase gene. Jpn J Cancer Res 1997; 88: 108-
10.
48. Campling BG, Baer K, Baker HM, Lam YM. Cole SPC. Do glutathione
and related enzymes play a role in drug resistance in small cell lung
cancer ctll lines? Br J Cancer 1993; 68: 327-35.
49. Kodera Y, Akiyama S, Isobe K, Kondo K, Ito K, Yamauchi M, Takagi
H. Expression of ?-glutathione S-transferase gene (GSTP1) in gastric
cancer: lack of correlation with resistance against cis-
diamminedichloroplatinum (II). Eur J Cancer 1994; 30A: 2158-62.
50. Mellish KJ, Kelland LR, Harrap KR. In vitro platinum drug
chemosensitivity of human cervical squamous cell carcinoma cell lines
with intrinsic and acquired resistance to cisplatin. Br J Cancer
1993; 68: 240-50.
51. Eichholtz-Wirth H, Reidel G, Hietel B. Radiation-induced
transient cisplatin resistance in murine fibrosarcoma cells
associated with elevated metallothionein content. Br J Cancer 1993;
67: 1001-6.
52. Lazo JS, Basu A. Metallothionein expression and transient
resistance to electrophilic antineoplastic drugs. Semin Cancer Biol
1991; 2: 267-71.
53. Hishikawa Y, Abe SI, Kinugasa S, Yoshimura H, Monden N.
Overexpression of metallothionein correlates with chemoresistance to
cisplatin and prognosis in esophageal cancer. Oncology 1997; 54: 342-
7.
54. Vaisman A, Vachenko M, Said I, Chaney SG. Cell cycle changes
associated with formation of Pt-DNA adducts in human ovarian
carcinoma cells with different cisplatin sensitivity. Cytometry 1997;
27: 54-64.
55. Hill BT, Scanlon KJ, Hansson J, Harstrick A, Pera M,
Fichtinger-Schepman AMJ, Shellard SA. Deficient repair of cisplatin-
DNA adducts identified in human testicular teratoma cell lines
established from tumours from untreated patients. Eur J Cancer 1994;
30A: 832-7.
56. Johnson SW, Swiggard PA, Handel LM, Godwin AK, Ozols RF, Hamilton
TC. Relationship between platinum-DNA adduct formation and removal
and cisplatin cytotoxicity in cisplatin-sensitive and resistant human
ovarian cancer cells. Cancer Res 1994, 54: 5911-6.
57. Turchi JJ, Li M, Henkels KM. Cisplatin-DNA binding specificity
of calf high mobility group I protein. Biochem 1996; 35: 2992-3000.
58.Ikeda S, Ozaki K. Action of mitochondrial endonuclease G on DNA
damaged by L-ascorbic acid, peplomycin, and cis-
diamminedichloroplatinum (II). Biochem Biophys Res Commun 1997,
235(2): 291-4.
59. Bissett D, McLaughlin K, Kelland LR, Brown R. Cisplatin-DNA
damage recognition proteins in human tumor extracts. Br J Cancer
1993; 67:742-8.
60. McLaughlin K, Coren G, Masters J, Brown R. Binding activities of
cis-platin-damage-recognition proteins in human tumor cell lines. Int
J Cancer 1993; 53: 662-6.
61. Brown R, Hirst GL, Gallagher WM, McIlwrath AJ, Margison GP, Zee
AG, Anthoney DA. HMLN1 expression and cellular responses of ovarian
tumor cells to treatment with cytotoxic anticancer agents. Oncogene
1997, 15(1): 45-52.
62. Lanzi C, Perego P, Supino R, Romanelli S, Pensa T, Carenini N,
Viano I, Colangelo D, Leone R, Apostoli P, Cassinelli G, Gambetta RA,
Zunino F. Decreased drug accumulation and increased tolerance to DNA
damage in tumor cells with a low level of cisplatin resistance.
Biochem Pharmacol 1998, 55(8): 1247-54.
63. Fishel R, Ewel A, Lescoe MC. Purified human MSH2 protein binds to
DNA containing mismatched nucleotides. Cancer Res 1994; 54: 5539-42.
64. Loeb LA. Microsatellite instability: marker of a mutator
phenotype in cancer. Cancer Res 1994; 54: 5059-63.
65. Chu G. Cellular responces to Cisplatin. J Biol Chem 1994; 269:
787-90.
66. Sorenson CM, Eastman A. Influence of cis-Diamminedichloroplatinum
(II) on DNA synthesis and cell cycle progression in excision repair
proficient and deficient hamster ovary cells. Cancer Res 1988; 48:
6703-7.
67. Li Q, Gardner K, Zhang L, Tsang B, Bostick-Bruton F, Reed E.
Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70 human
ovarian cancer cells. J Biol Chem 1998, 273 (36): 23419-25.
68. Husain A, He G, Venkatraman ES, Spriggs DR. BRCA1 up-regulation
is associated with repair-mediated resistance to cis-
diamminedichloroplatinum (II). Cancer Res 1998, 58 (6): 1120-3.
69. Mestdach N, Pommery N, Saucier JM, Hecquet B, Founier C,
Slomianny C, Teissier E, Henichart JP. Chemoresistance to doxorubicin
and cisplatin in a murine cell line. Analysis of P-Glycoprotein,
topoisomerase II activity, glutathione and related enzymes.
Anticancer Res 1994; 14: 869-74.
70. Kondo H, Kanzawa F, Nishio K, Saito S, Saijo N. In vitro and
in vivo effects of cisplatin and etoposide in combination on small
cell lung cancer cell lines. Jpn J Cancer Res 1994; 85: 1050-6.
71. Jong S, Timmer-Bosscha H, Vries EGE, Mulder NH. Effect of
